Indo Us Bio Tech Limited has announced that its board of directors will meet on Friday, May 29, 2026. The primary agenda for the meeting includes the consideration of the audited financial results for the fourth quarter and the fiscal year ended March 31, 2026, in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Agenda Items

The board will deliberate on several key financial documents. Specifically, the directors will consider:

• The Audited Financial Results for the fourth quarter and year ended March 31, 2026.
• The audited Balance Sheet as at March 31, 2026.
• The Statement of Profit and Loss for the year ended March 31, 2026.
• Other corporate matters as may be brought before the board.

Trading Window Closure

In compliance with regulatory norms, the company has informed the exchanges regarding the closure of the trading window. The window was closed on April 1, 2026, and will remain shut until May 30, 2026. This closure period includes both the start and end dates to ensure confidentiality and prevent insider trading during the sensitive period surrounding the financial results announcement.

The meeting notice was signed by Ms. Dimpy Joshi, Company Secretary & Compliance Officer, on behalf of indo us bio-tech .

Indo US Bio-Tech Limited has announced the appointment of Mrs. Hemanshi Darsh Soni as Additional Director in the capacity of Non-Executive Independent Director. The appointment was formalized through a board resolution passed on 21.04.2026, pursuant to the provisions of the Companies Act, 2013 and SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

Appointment Details

The company's board has appointed Mrs. Hemanshi Darsh Soni (DIN: 11659183) for a period of 5 years effective from 21.04.2026. The appointment is subject to approval of shareholders in the General Meeting.

Director Profile and Independence

Mrs. Hemanshi Darsh Soni brings experience from the service sector and is recognized for building high-performance teams, implementing strong sales, marketing and service networks, and establishing robust operational processes. The company has confirmed that she is not related to any of the existing directors or key managerial personnel of Indo US Bio-Tech Limited.

Key independence criteria met:

• No relationship with existing directors or key managerial personnel
• Does not hold directorship in any other listed entity
• Not debarred from holding director position by SEBI or any other authority

Regulatory Compliance

The appointment has been made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has provided all required details as per SEBI Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, covering appointment particulars, terms, director profile, and independence confirmations.

The appointment strengthens the company's board composition with an experienced professional from the service sector, enhancing corporate governance through independent oversight.